Related Experiment Video
Updated: May 11, 2026

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
Published on: October 13, 2023
IDAP: an integrated literature- and knowledge-graph-driven evidence prioritization pipeline for precision oncology
Yebin Ryu1,2, Haeun Jung1,3, Joon-Yong An1,2,3,4
1Department of Integrated Biomedical and Life Science, Korea University, Seoul, 02841, Republic of Korea.
Motivation:
Advances in tumor sequencing enable routine detection of dozens to hundreds of somatic alterations per patient, yet only a minority can be linked to established therapeutic evidence. Curated resources such as OncoKB provide high-quality variant-drug annotations but remain limited in coverage, particularly for rare or low-frequency variants. This coverage gap motivates computational frameworks that can integrate curated, literature-derived, graph-based, and clinical-trial evidence to prioritize therapeutic hypotheses for expert review.
Results:
We developed the Integrated Drug Annotation Pipeline (IDAP), a modular framework that combines four complementary evidence streams: curated variant-drug associations from OncoKB, literature-derived gene-drug mention counts from PubMed abstracts, graph-based drug prioritization using a TxGNN-derived biomedical knowledge graph, and cancer-specific clinical-trial evidence from ClinicalTrials.gov. Given a cancer type and a MAF file, IDAP generates patient-level reports summarizing detected variants, ranked therapeutic hypotheses, supporting evidence layers, and relevant clinical trials. Evaluated across five cancer types (n = 50 samples), IDAP expanded evidence-linked therapeutic hypotheses beyond curated databases alone. Among patients without OncoKB recommendations (26/50), IDAP identified a median of 87 candidate drugs (range: 2-473). To reduce cross-source scale imbalance, the final ranking used within-sample percentile normalization with fixed bonuses for curated evidence, multi-source support, and trial linkage. Under this revised ranking, 24/50 top-ranked candidates were supported by at least two evidence sources and 44/50 had associated ClinicalTrials metadata. In an exploratory external CIViC comparison, IDAP recovered at least one matched CIViC-supported therapy in 28/41 eligible samples, with 13/41 appearing within the top 10 candidates. These outputs are intended to support evidence triage and translational interpretation rather than direct treatment recommendation.
Availability And Implementation:
IDAP is freely available at https://github.com/joonan-lab/IDAP-pipeline, with full documentation at https://joonan-lab.github.io/IDAP-pipeline. An archived snapshot of the code used in this study is deposited on Zenodo (DOI: https://doi.org/10.5281/zenodo.19301367).
Insights
The Integrated Drug Annotation Pipeline (IDAP) identifies potential cancer drug therapies by integrating multiple evidence sources. This computational framework expands therapeutic hypotheses beyond curated databases for personalized treatment strategies.
Area of Science:
- Computational biology
- Genomics
- Translational oncology
Background:
- Tumor sequencing generates numerous somatic alterations, but few have established therapeutic links.
- Existing resources like OncoKB have limited coverage, especially for rare variants.
- A computational approach is needed to integrate diverse evidence for prioritizing therapeutic hypotheses.
Purpose of the Study:
- To develop a computational framework for integrating multiple evidence streams to prioritize therapeutic hypotheses for cancer patients.
- To expand the identification of potential drug therapies beyond currently curated databases.
Main Methods:
- Developed the Integrated Drug Annotation Pipeline (IDAP), a modular framework.
- Integrated four evidence streams: curated variant-drug associations (OncoKB), literature mentions (PubMed), graph-based prioritization (TxGNN), and clinical trial data (ClinicalTrials.gov).
- Generated patient-level reports with ranked hypotheses, supporting evidence, and clinical trials.
Main Results:
- IDAP expanded evidence-linked therapeutic hypotheses beyond curated databases.
- For patients without OncoKB recommendations, IDAP identified a median of 87 candidate drugs.
- Top-ranked candidates were frequently supported by multiple evidence sources and linked to clinical trials.
Conclusions:
- IDAP effectively prioritizes therapeutic hypotheses by integrating diverse data sources.
- The pipeline aids in evidence triage and translational interpretation for personalized cancer therapy.
- IDAP enhances the identification of potential drug candidates for underrepresented variants.
More Related Videos
05:47Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Nursing Clinical Information System
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include: